Skip to content

Clinical study on the efficacy and safety of Jieyuwan in the treatment of epidemic stress, anxiety and depression (stagnation of liver Qi syndrome)

Clinical study on the efficacy and safety of Jieyuwan in the treatment of epidemic stress, anxiety and depression (stagnation of liver Qi syndrome)

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039536
Enrollment
Unknown
Registered
2020-10-30
Start date
2020-11-15
Completion date
Unknown
Last updated
2021-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety and depression

Interventions

Sponsors

Dongfang Hospital Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) They voluntarily signed informed consent and were willing to participate in the research; (2) novel coronavirus pneumonia affects the state of anxiety and depression; (3) The total score of hospital anxiety and depression scale was more than 16, and the total score of anxiety and / or depression items was more than 8; (4) According to the diagnosis of liver qi stagnation syndrome; (5) Age: 18-65 years old (including 18 years old and 65 years old).

Exclusion criteria

Exclusion criteria: (1) Patients with overdose of excitatory drugs, withdrawal reaction of hypnotic sedative drugs or anti anxiety drugs, and patients with acute panic disorder, obsessive-compulsive disorder, mania or schizophrenia; (2) Patients with anxiety disorder or depression diagnosis; (3) Patients who have suicide history or suicide tendency in the past; (4) Patients with organic mental disorders, psychoactive substances, non addictive substances and postpartum depression; (5) Patients with severe primary diseases of heart, brain, liver, kidney, hematopoiesis and urogenital system; (6) The patients who had used antidepressant, anti anxiety, antipsychotic western medicine and the same kind of traditional Chinese medicine treatment within 4 weeks before enrollment; (7) Those who are allergic to any component of the test drug or allergic constitution (allergic to more than two kinds of food or drugs); (8) Pregnant or preparing for pregnancy and lactation; (9) Patients who participated in or were participating in other clinical trials within one month before enrollment.

Design outcomes

Primary

MeasureTime frame
Hospital Anxiety and Depression Scale;

Secondary

MeasureTime frame
Self-rating Depression Scale;Self-rating Anxiety Scale;FIRST-C;Pittsburgh sleep quality index;TCM Constitution identification scale;TCM Syndrome Scale;

Countries

China

Contacts

Public ContactRongjuan Guo

Dongfang Hospital Beijing University of Chinese Medicine

dongfanguorongjuan@163.com+86 18611377633

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026